In the BioHarmony Drug Report Database
Carfilzomib
Kyprolis (carfilzomib) is a protein pharmaceutical. Carfilzomib was first approved as Kyprolis on 2012-07-20. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against proteasome subunit beta type-5. Kyprolis’s patents are valid until 2033-02-27 (FDA).
Trade Name
|
Kyprolis |
|---|---|
Common Name
|
carfilzomib |
ChEMBL ID
|
CHEMBL451887 |
Indication
|
multiple myeloma |
Drug Class
|
Proteozome inhibitors |
Image (chem structure or protein)